Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, an estimated 235,760 new cases of lung cancer (~85% NSCLC), 281,550 new cases of breast cancer (10-15% triple-negative), 3,000 new cases of…
Owkin announces a $180 million investment from Sanofi as part of a broader strategic collaboration, bringing the company's valuation above $1 billion and…
Sanofi is discontinuing development of tusamitamab ravtansine, a CEACAM5-targeting antibody-drug conjugate, after the Phase 3 CARMEN-LC03 study failed to show…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Sanofi made a $180M equity investment in Owkin and entered a three-year strategic collaboration in four cancer types (NSCLC, TNBC, mesothelioma, multiple myeloma) with $90M in research payments plus milestones. The deal leverages Owkin's federated learning AI for biomarker discovery and clinical trial design. The collaboration was executed and has since deepened: in March 2024 the partners expanded it into AI-driven drug positioning across Sanofi's immunology pipeline, and on June 5, 2026 they announced a new five-year agreement under which Owkin builds bespoke AI-agent biopharma tools for Sanofi powered by Owkin's K Pro AI-scientist platform (financial terms of the 2024 and 2026 expansions undisclosed).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Owkin, Inc. (this deal) | 2021 | $270M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2021 deals · Sanofi SA deals · Hematology deals